OTCPK:IGXT (Canada) Also trade in: Canada Germany

Intelgenx Technologies Corp

$ 0.5 -0.02 (-2.99%)
Volume: 26,257 Avg Vol (1m): 157,765
Market Cap $: 46.35 Mil Enterprise Value $: 45.78 Mil
P/E (TTM): 0.00 P/B: 6.02
Earnings Power Value -0.96
Net Current Asset Value 0.03
Tangible Book 0.08
Projected FCF -0.44
Median P/S Value 0.32
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.07
Cash-To-Debt ranked lower than
91.74% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
IGXT: 1.07
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.07, Med: 3.18, Max: 10000
Current: 1.07
0.07
10000
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
88.47% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
IGXT: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.4, Med: 0.59, Max: 0.9
Current: 0.43
-0.4
0.9
Debt-to-Equity 1.03
Debt-to-Equity ranked lower than
96.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
IGXT: 1.03
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -5.13, Med: 0.59, Max: 18.8
Current: 1.03
-5.13
18.8
Debt-to-EBITDA -0.94
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
IGXT: -0.94
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -7.02, Med: -2.76, Max: 1.09
Current: -0.94
-7.02
1.09
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.84
DISTRESS
GREY
SAFE
Beneish M-Score -2.48
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -135.24%
WACC 13.52%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -464.57
Operating Margin ranked higher than
51.39% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
IGXT: -464.57
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -555.91, Med: -140.55, Max: 27.2
Current: -464.57
-555.91
27.2
Net Margin % -521.34
Net Margin ranked lower than
50.38% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
IGXT: -521.34
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -557.27, Med: -162.29, Max: 25.34
Current: -521.34
-557.27
25.34
ROE % -238.77
ROE ranked lower than
78.16% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
IGXT: -238.77
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -238.77, Med: -71.77, Max: 25.47
Current: -238.77
-238.77
25.47
ROA % -72.00
ROA ranked lower than
53.69% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
IGXT: -72
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -132.11, Med: -41.57, Max: 16.99
Current: -72
-132.11
16.99
ROC (Joel Greenblatt) % -147.63
ROC (Joel Greenblatt) ranked higher than
69.11% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
IGXT: -147.63
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1885.53, Med: -276.2, Max: 54.17
Current: -147.63
-1885.53
54.17
3-Year Total Revenue Growth Rate -29.00
3-Year Revenue Growth Rate ranked higher than
87.71% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
IGXT: -29.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -9.9, Max: 192.4
Current: -29.7
0
192.4

» IGXT's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:IGXT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:AQB LSE:MTPH XPAR:ONXEO NAS:INNT OHEL:BIOBV NAS:PLXP NAS:VBLT OSTO:ACE NAS:AZRX NAS:ENTX NAS:ALRN NAS:MBRX TSE:6090 NAS:CLDX OTCPK:BCDA OSTO:ASAP TSE:4585 TSE:4575 NAS:OPNT LSE:DEST
Traded in other countries IGX.Canada 0IL.Germany
Address 6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Intelegenx offers its partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing.

Ratios

Current vs industry vs history
PB Ratio 6.02
PB Ratio ranked lower than
94.70% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
IGXT: 6.02
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4.21, Med: 9.65, Max: 215
Current: 6.02
4.21
215
PS Ratio 20.83
PS Ratio ranked lower than
50.41% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
IGXT: 20.83
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 5, Med: 13.33, Max: 97.14
Current: 20.83
5
97.14
EV-to-EBIT -5.03
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
IGXT: -5.03
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -117.2, Med: -10.2, Max: 375.1
Current: -5.03
-117.2
375.1
EV-to-EBITDA -5.45
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
IGXT: -5.45
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -389.6, Med: -10.15, Max: 531.1
Current: -5.45
-389.6
531.1
EV-to-Revenue 23.29
EV-to-Revenue ranked lower than
50.97% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
IGXT: 23.29
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 5.3, Med: 13.55, Max: 96.5
Current: 23.29
5.3
96.5
Current Ratio 4.08
Current Ratio ranked lower than
78.68% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
IGXT: 4.08
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.66, Med: 3.59, Max: 11.6
Current: 4.08
0.66
11.6
Quick Ratio 3.93
Quick Ratio ranked lower than
74.67% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
IGXT: 3.93
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.66, Med: 3.59, Max: 11.6
Current: 3.93
0.66
11.6
Days Sales Outstanding 122.94
Days Sales Outstanding ranked higher than
55.69% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
IGXT: 122.94
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 43.77, Med: 112.56, Max: 390.59
Current: 122.94
43.77
390.59

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.30
3-Year Share Buyback Rate ranked higher than
87.63% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
IGXT: -5.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -120.3, Med: -15.5, Max: -1.8
Current: -5.3
-120.3
-1.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.25
Price-to-Tangible-Book ranked lower than
91.61% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
IGXT: 6.25
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 4.21, Med: 9.86, Max: 215
Current: 6.25
4.21
215
Price-to-Median-PS-Value 1.56
Price-to-Median-PS-Value ranked lower than
55.75% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
IGXT: 1.56
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.45, Med: 1.15, Max: 6.89
Current: 1.56
0.45
6.89
Earnings Yield (Joel Greenblatt) % -19.85
Earnings Yield (Greenblatt) ranked higher than
52.73% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
IGXT: -19.85
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -39.4, Med: -8.3, Max: 5.3
Current: -19.85
-39.4
5.3

More Statistics

Revenue (TTM) (Mil) $ 2
EPS (TTM) $ -0.14
Beta 1.96
Volatility % 104.01
52-Week Range $ 0.43 - 1.83
Shares Outstanding (Mil) 63.62

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N